Opinion|Videos|April 22, 2026
Considerations for Targeted Agents and Rechallenge in R/R Follicular Lymphoma
Author(s)Loretta J. Nastoupil, MD, Amitkumar Mehta, MD
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss the role of targeted therapies and rechallenging with certain classes of agents in follicular lymphoma.
Advertisement
Episodes in this series
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss considerations for targeted therapies and the role of rechallenge strategies in relapsed/refractory follicular lymphoma. Nastoupil reviews how prior exposure to CD19-directed therapies may influence subsequent treatment selection and sequencing. Mehta highlights emerging evidence on CD19 expression and the feasibility of reusing or sequencing targeted agents without compromising future efficacy.
Advertisement
Related to this article
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Sylvester cancer researchers became wildland firefighters themselves to study, from the inside, cancer risks tied to the job.
The FDA has granted breakthrough device designation to Merlin CP-GEP, a clinicopathologic gene expression profile test for early-stage cutaneous melanoma.
Brian Myre, MD, discusses phase 1 data with the novel in situ SYNC-T Therapy SV-102 and the ongoing phase 2 LEGION-100 study in prostate cancer.
Drs Nunnery and Iyengar discuss FAQs about the metabolic effects of breast cancer therapy and the expanding role of GLP-1 receptor agonists in oncology.
Advertisement
Advertisement
Trending on OncLive
1
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
2
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
3
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
4
Surgeons, Medical Oncologists, and Radiation Oncologists Debate Current Thresholds for Systemic Therapy in EGFR-Mutated NSCLC
5